cells

Also called U266 or U-266. Lymphoblast plasmacytoma established from the peripheral blood of a 53-year-old man with IgE-secreting myeloma (refractory, terminal) in 1968.

Cell Type:

B cell

Tissue Origin:

blood

Species:

human

Research Area:

Cancer Research/Cell Biology

Immunotherapy / Hematology

Cell Characteristics:

Suspension

Transfection Information

Lonza Optimized Protocol
Optimization Guideline

Filter:

The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.

Kit	Program	Cells	Efficiency	Viable Cells	Substrate		Format	Platform
C	X-005	2e6	84-88%	90-92%	Plasmid (general)	2 µg	100 µl	I/II/2b
SF	DY-100	4e5	88-90%	61-65%	Plasmid (general)	0.4 µg	20 µl	4D X-Unit
SF	DY-100	2e6	89-93%	56-80%	Plasmid (general)	2 µg	100 µl	4D X-Unit

Citations

Antimyeloma effects of a sesquiterpene lactone parthenolide

Categories:

Transfection

Authors:

Suvannasankha A, Crean CD, Shanmugam R, Farag SS, Abonour R, Boswell HS, Nakshatri H

In:

Clin Cancer Res (2008) 14(6): 1814-22

The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells

Categories:

Transfection

Authors:

Pei XY, Dai Y, Rahmani M, Li W, Dent P and Grant S

In:

Clin Cancer Res (2005) 11(12): 4589-4600

U266B1

Transfection Information

Citations